New drug combo aims to fight recurrent cervical cancer
NCT ID NCT05990803
First seen Jun 26, 2026 · Last updated Jun 27, 2026 · Updated 1 time
Summary
This phase II trial tests two experimental drugs, BL-B01D1 and SI-B003, alone or together, in 130 women with recurrent or metastatic cervical cancer that hasn't responded to standard treatments. The goal is to see if these drugs can shrink tumors or slow the cancer's growth. Participants receive the drugs through an IV, and the study will also find the best dose and check for side effects.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
BL-B01D1 (izalontamab brengitecan) and SI-B003, given by intravenous infusion
What this could lead to
If successful, this could offer a new treatment option for people with cervical cancer that has returned or spread, potentially shrinking tumors or slowing disease progression.
What could go wrong
This is an early phase II trial with only 130 participants, so results may not apply to everyone. The drugs may cause side effects or not work as hoped, and the optimal dose is still being explored.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for CERVICAL CANCER are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Cancer Hospital Chinese Academy of Medical Sciences
RECRUITINGBeijing, Beijing Municipality, China
Contact